Bull and Bear
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Bull and Bear
Verdict: Watchlist — the Q4 FY26 print in May 2026 is days away, and pre-positioning at 97x trailing into a credibility-impaired, pledge-encumbered, illiquid micro-cap when the resolver is observable in weeks is hard to justify. The Bear's case rests on structural facts management already conceded — FY27 ambition reset from 14% to 8–9% EBITDA, FY26 revenue walked from $211M toward $167M, and 10 of 12 quantified promises since IPO missed or reset. The Bull's case is mechanical and largely outside management's control — palm oil reversion, insurance recoveries, and Modasa Phase II — and Q3 FY26's 8% EBITDA print is genuine evidence the recovery is not just rhetoric. The decisive tension is whether FY24's 12% EBITDA was a steady state or an IPO-disclosure peak built on inventory and capex management; only a clean Q4 FY26 print can answer it. Until that print lands, the institutional move is to wait, not to anchor on either $5.33 or $2.13.
Bull Case
Bull's price target: $5.33 over 12–18 months, anchored to a peer-relative multiple — FY27 normalized EBITDA at 11% on $213M revenue → ~$14.9M PAT → ~$0.135 EPS at 45x (still a 30% discount to Bikaji's 65x to allow for the size and quality gap). The primary catalyst is the Q4 FY26 earnings print (May 2026): EBITDA margin ≥9% on revenue ≥$42.6M, with concurrent insurance reconciliation against the $20.4M cover. The Bull's own disconfirming signal is a Q4 FY26 EBITDA below 8% on a clean (ex-recovery) basis, or cumulative insurance settlement under $8.2M through FY27 — either tells the Bull that FY23–24's 12–14% margin band was a peak built on inventory and capex management, not a structural mean.
Bear Case
Bear's downside target: $2.13 (–28% from $2.95) over 12–18 months, applying a 25x cycle-mid multiple to FY24 normalized EPS of $0.10. Cross-checks converge in a $1.92–$2.13 range: FY27 guided ~$0.06 EPS × 30x = $1.92; Bikaji-parity 65x on FY26 trailing of ~$0.03 = $2.08. The primary trigger is the Q4 FY26 EBITDA print in May-2026 — Q3 FY26 printed 7.6% with insurance recoveries flowing above the line, and an 8%-or-lower clean print opens the next round of consensus cuts and re-tests the FY27 reset. The Bear's own cover signal is two consecutive clean quarters of EBITDA ≥11% with no exceptional/insurance tailwind, AND Modasa gross margin holding 27%+, AND non-Gujarat revenue growing 35%+ on an un-fire-distorted base — that combination would validate FY24's 12% as a structural mean and pull normalized EPS toward $0.11–$0.13.
The Real Debate
Verdict
Watchlist. The Bear carries more structural weight: a credibility ledger (10 of 12 missed/reset promises, FY27 ambition halved on margin), a 9.72% promoter pledge into 0.06%-of-mcap daily liquidity, and a 97x trailing multiple on a fire-distorted base together describe a stock pricing a Bikaji-class recovery management has serially walked back. The single most important tension is margin trajectory — cycle or reset — and the Bear has the larger weight of evidence that pre-fire FY25 was already drifting below guide. The Bull could still be right: palm oil has normalized, Modasa Phase II is operational, $4.0–4.5M of insurance recoveries plausibly remain, and Q3 FY26 already printed 8% — a clean Q4 FY26 ≥9% on revenue ≥$42.6M would validate the entire mean-reversion thesis and force a peer-relative re-rate. The verdict flips to Lean Long if Q4 FY26 prints ≥9% EBITDA on an ex-recovery basis with no incremental pledge disclosed; it slides to Lean Short / Avoid Ownership if margin prints ≤8% (especially with recoveries still flowing above the line) or any new pledge appears. Until that print lands, paying 97x trailing for a binary that resolves within weeks does not earn the wait.